Funding
NIH - R01HD110107
Big data apprOaches (fOr Safe Therapeutics in Healthy Pregnancies (BOOST-HP)
Funder: National Institutes of Health
PI: Judith Maro, Harvard Pilgrim Healthcare Institute
Period of Performance: August 01, 2022 - April 01, 2026
Objectives
Our specific aims are: (Aim 1) To scan for associations between (1a) pregnancy loss and antecedent prenatal exposures on the individual drug, chemical and therapeutic class level; and (1b) the 50 most prevalent drugs in pregnancy with incomplete information on teratogenic risk and a broad selection of live birth adverse outcomes; and (1c) to prioritize signals via expert panel review. (Aim 2) To employ careful pharmacoepidemiologic designs to evaluate the two top prioritized signals involving (2a) pregnancy loss, and (2b) an adverse livebirth outcome. To control for confounding and measurement biases, these studies will employ previously validated measures, which are further enhanced via linkage to fetal death and birth certificate data for a cohort subsample to evaluate unmeasured confounding and conduct probabilistic sensitivity analyses on outcome and exposure misclassification.